For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
Pfizer was rated first by five of these key physician groups, as well as urologists, nephrologists, emergency medicine specialists and neurosurgeons. The company also was ranked number one by nurse practitioners and physician assistants.
The report also examined sales force value among physician specialty groups. The leading sales forces among select groups of specialists:
•Â Allergists: Aventis Pharmaceuticals, Parsippany, NJ.
•Â OB/GYNs: Wyeth-Ayerst Laboratories, Philadelphia, PA.
•Â Oncologists: Bristol-Myers Squibb Co., New York.
•Â Orthopedic surgeons: Merck & Co. Inc., Whitehouse Station, NJ.
•Â Psychiatrists: Eli Lilly and Co., Indianapolis.
These rankings come from "Pharmaceutical Sales Force Structures & Strategies 2000-2001," the 13th edition of Scott-Levin's annual study of pharmaceutical sales forces. Thirty-three physician specialty groups and other healthcare providers were surveyed for this year's report. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.